Glint Pharmaceuticals Announces Formation of Clinical Advisory Board

Share Article

Clinical Advisors to Guide Development of Glint Drug Delivery contact lens technology

Glint Pharmaceuticals announces the formation of a clinical advisory board composed of notable and experienced clinicians in ophthalmology and optometry.

The clinicians on the advisory board include: Dr. Mark Abelson, Founder ORA, Inc., Dr. Cynthia Matossian, Medical Director, Matossian Eye Associates, an affiliate of Prism Vision Group, Dr. James Thimons, Medical Director, Ophthalmic Consultants of Connecticut, Dr. Mark Blecher, Professor Ophthalmology, Wills Eye Hospital and Dr. Paul Karpecki, Director, Kentucky Eye Institute,

"We are grateful to have such an experienced and knowledgeable group of clinicians join our advisory board to guide the development of our drug delivery technology to treat significant medical eye disease," says Chris Adams CEO.

About Glint
Glint Pharmaceuticals, a Massachusetts company, is developing proprietary drug delivery technology for the treatment and prevention of ocular infections and diseases. Examples of diseases to be treated include, Covid-19 infection, glaucoma, ocular inflammation, conjunctivitis, allergic rhinitis, and dry eye. Over 40 million Americans suffer from ocular surface disease. The technology has the potential to increase drug efficacy and patient compliance.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Adams
Visit website